Important Safety Information Full Prescribing Information

If you are a healthcare professional outside of the U.S., please visit Aloxi.net

Welcome US Healthcare Professionals

ALOXI provides powerful CINV prevention that can’t be ignored

Welcome to ALOXI.com, your source for information on ALOXI^®.

Here you will find the latest information about ALOXI for healthcare professionals. You also will find patient education materials on chemotherapy-induced nausea and vomiting (CINV). Information on this site will be updated regularly.

This information is intended only for U.S. healthcare professionals.

Indication

In adults, ALOXI^® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

Aloxi is contraindicated in patients known to have hypersensitivity to the drug of any of its components
Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)

For more information about ALOXI, please see Full Prescribing Information

Sitemap | Legal Notice and Disclaimers | Privacy

This information is intended for use by healthcare professionals in the United States only. Eisai Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.